Group 1 - Curanex Pharmaceuticals Inc. has priced its initial public offering (IPO) of 3,750,000 shares at $4.00 per share, aiming for gross proceeds of $15 million [1] - The IPO is expected to close on August 27, 2025, and shares will begin trading on the Nasdaq Capital Market under the ticker symbol "CURX" [1] - Underwriters have an option to purchase an additional 562,500 shares within 45 days of the offering's close [1] Group 2 - Proceeds from the offering will be used for the development of the lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required studies and IND application preparation [2] - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with Phyto-N being a botanical extract with proven anti-inflammatory properties [7][8] - Phyto-N has been validated in animal models for six inflammatory diseases, with the primary indication being moderate to severe ulcerative colitis [8] Group 3 - Dominari Securities LLC is the lead underwriter for the offering, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [3] - A registration statement for the offering was filed with the SEC and declared effective on August 12, 2025 [4] - The final prospectus related to the offering will be available on the SEC's website [4][5]

Company Overview - Bowman Consulting Group Ltd. is a national engineering services and program management firm headquartered in Reston, Virginia [2] - The company employs approximately 2,500 individuals and operates across 100 locations in the United States [2] - Bowman provides a wide range of services including planning, engineering, geospatial, construction management, commissioning, environmental consulting, and land procurement [2] Conference Participation - Bowman Consulting Group will participate in D.A. Davidson's 24th Annual Diversified Industrials & Services Conference scheduled for September 17-19 [1] - The conference will take place at The Four Seasons Hotel in Nashville, Tennessee [1]

Core Insights - DraftKings Inc. is launching a monthlong campaign for Responsible Gaming Education Month (RGEM) to promote responsible gaming through a sweepstakes offering NFL tickets and a trip to Super Bowl LX [1][2] - The campaign encourages customer engagement with responsible gaming tools like My Budget Builder and My Stat Sheet, aiming to foster a more informed gaming culture [2][4] Group 1: Campaign Details - The sweepstakes will run from August 26 to September 8, allowing customers to win NFL regular season tickets by using My Budget Builder [2] - Each week will introduce new responsible gaming engagement methods, with additional ticket giveaways and a grand prize trip to Super Bowl LX for using My Stat Sheet [2][3] Group 2: Tool Highlights - My Budget Builder, launched in June 2025, builds on the success of My Stat Sheet, which has been utilized by approximately 3.4 million customers to track their gaming activity [3] - DraftKings emphasizes the integration of responsible gaming tools throughout the customer journey, reinforcing its commitment to responsible play [4] Group 3: Company Commitment - DraftKings is dedicated to providing a fun and responsible gaming experience, sharing a new Code of Responsible Play with customers to promote responsible behavior [4] - The company aims to maintain responsible gaming as a core aspect of its product design and long-term strategy as it continues to grow [4][6]

Company Overview - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [1] - The company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [1] Investor Engagement - Management will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 5, 2025, and the H.C. Wainwright Global Investment Conference on September 9, 2025 [3] - The Morgan Stanley Global Healthcare Conference is scheduled for September 10, 2025, where a fireside chat will take place [3] - These events will include one-on-one meetings and webcasts accessible via the Altimmune website [3]

Company Announcement - FuelCell Energy, Inc. will release its third quarter 2025 results on September 9, 2025, before the stock market opens [1] - Following the results announcement, the company will host a conference call with investors at 10:00 a.m. Eastern Time on the same day [1] Conference Call Details - The conference call will be accessible via webcast on the company's website or by telephone [1] - A replay of the conference call will be available approximately two hours after the conclusion of the call on the company's Investors' page [2] Company Overview - FuelCell Energy provides clean and reliable energy solutions that enable customers to access power quickly and manage emissions [3] - The company's systems are efficient, scalable, and fuel-flexible, operating on natural gas, biofuels, or hydrogen, and provide steady baseload electricity [3] - With over 55 years of expertise and nearly 200 modules deployed, FuelCell Energy assists customers in achieving their energy goals [3]

Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platformBria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer This study was conducted in collaboration with the NCI PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “C ...

RYE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of Bancroft Fund Ltd. (NYSE American: BCV) (the “Fund”) increased the quarterly distribution to $0.35 per share. The increased quarterly distributions will commence with the distribution payable in December 2025. This is a 10% increase from $0.32 per share, bringing the annualized distribution rate to $1.40 from $1.28 per share. The increase underscores the strength of the Fund’s NAV total return of 20% year to date. Investors should careful ...

Core Insights - Draganfly Inc. is strategically positioned to support Canada's $2 billion military aid package to Ukraine, with over $220 million allocated for drone and electronic warfare capabilities [1][2] - The company's extensive experience in drone technology and its active involvement in Ukraine since 2022 enhance its ability to contribute to defense initiatives [2][3] - Draganfly's capabilities include advanced UAV solutions, counter-drone systems, and support for ISR, demining, and logistics [3][4] Strategic Alignment - Canada's military aid underscores its commitment to defending democracy and resisting authoritarianism, with a significant portion of funding directed towards advanced drone technologies [2] - The partnership between Canadian and Ukrainian defense companies is emphasized, with Draganfly's engineering expertise being a key asset [2][3] Military-Grade Capabilities - Draganfly has a proven track record in defense and humanitarian response, showcasing its advanced drone systems and counter-drone technologies [3] - The company is expanding its capabilities through domestic and international defense contracts, R&D investments, and partnerships with NATO-aligned nations [3] Company Overview - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in the industry [4] - The company focuses on delivering reliable technology for various applications, including public safety, agriculture, and industrial inspections [4]

Core Insights - Gilat Satellite Networks Ltd. has signed a $25 million agreement with Pronatel to modernize the Regional Broadband network in the Cusco region of Peru, enhancing connectivity for public institutions [1][2][3] - The upgraded network will provide high-speed internet of 200 Mbps to approximately 208 public institutions and 69 public free WiFi hotspots, improving access to essential services such as education and healthcare [2][3] - This initiative reflects Gilat's ongoing commitment to digital inclusion and its partnership with the Peruvian State, aiming to strengthen critical public services in remote areas [3][4] Company Overview - Gilat Satellite Networks Ltd. is a leading global provider of satellite-based broadband communications, with over 35 years of experience in delivering technology solutions for various applications [4][5] - The company offers a comprehensive portfolio that includes cloud-based platforms, high-performance satellite terminals, and integrated ground systems for both commercial and defense markets [5][6] - Gilat's products support multiple applications, including government, defense, broadband access, and critical infrastructure, while adhering to stringent service level requirements [6]

Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [2] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to inhibit the activity of B cells involved in autoimmune diseases without depleting them [2] - Zenas aims to leverage its experienced leadership and disciplined product acquisition strategy to identify and develop candidates that provide superior clinical benefits for patients [2] Upcoming Events - Zenas will present at the Citi's 2025 Biopharma Back to School Conference on September 2, 2025, at 1:00 p.m. ET [3] - The company will also participate in the Cantor Global Healthcare Conference 2025 on September 3, 2025, at 8:35 a.m. ET [3] - Additionally, Zenas is scheduled to present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, at 7:45 a.m. ET [3]